NCT01837511View on ClinicalTrials.gov

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

CompletedOBSERVATIONAL
Enrollment

377

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Interventions
OTHER

Data acquisition and analysis

Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.

Trial Locations (3)

169608

GSK Investigational Site, Singapore

137-701

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Songpa-gu, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01837511 - Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients | Biotech Hunter | Biotech Hunter